Saturday, May 21, 2022



DCGI grants restricted EUA to Covaxin for 6-12 age group

New Delhi, April 26, 2022- The Drugs Controller General of India (DCGI) on Tuesday approved the restricted emergency use authorisation (EUA) to Bharat Biotech’s Covaxin for children between the age of 6-12 years, sources said.

The DGCI has asked vaccine manufacturer to submit safety data including the data on adverse event with due analysis every 15 days for the first two months and monthly thereafter upto 5 months, said the source familiar with the development.

This development comes after the Subject Expert Committee (SEC) discussed recommendations for the restricted emergency use of Covaxin in children aged between 2-12 years.

However, the SEC, after a meeting on Thursday, had recommended restricted emergency use of Biological E’s Covid-19 vaccine, Corbevax, in children aged 5-12 years.  (Agency)

Subscribe to YesPunjab Telegram Channel & receive important news updates

- Advertisement -

Yes Punjab - TOP STORIES

Punjab News

Sikh News

Transfers, Postings, Promotions

- Advertisement -spot_img

Stay Connected






Musk wants to investigate bots before Twitter deal – by Narvijay Yadav

The blue bird of Twitter is in trouble once again. The question has arisen whether Tesla CEO Elon Musk will confirm the deal or...

Fault lines widening amongst Indian Muslim religious leaders – by Asad Mirza

New Delhi, May 16, 2022- Recent outreach activities by Muslim leaders across India relays very disturbing and hopeless signs, instead of formulating a strategy...

Growing heat, vanishing wheat, shrinking size – by Narvijay Yadav

When I bought a packet of sandwich bread in the morning, the vendor said that the ‘price has increased’. Then I saw news in...


Health & Fitness

Cold virus caused 100,000 deaths worldwide in kids in 2019: Lancet

London, May 20, 2022- Acute lower respiratory infection caused by Respiratory Syncytial Virus (RSV) was responsible for more than 100,000 deaths in children under five across the globe in 2019, according to a study published in The Lancet. The study is the first to examine RSV disease burden in narrow age brackets, reporting that there were over 45,000 deaths in...

Gadgets & Tech